Literature DB >> 9740788

Regulated lentiviral packaging cell line devoid of most viral cis-acting sequences.

M Kaul1, H Yu, Y Ron, J P Dougherty.   

Abstract

Packaging cell lines derived from human immunodeficiency virus-1 (HIV-1) are promising tools for in vivo somatic cell gene therapy protocols due to the ability of lentiviruses to infect nondividing cells. We describe here the generation of a safe, stable HIV-1 packaging cell line capable of expressing all of the HIV-1 structural, enzymatic, and regulatory proteins but lacking majority of the cis-acting sequences. The use of an inducible expression system circumvented the cytotoxic and cytostatic effects associated with the expression of some of the HIV-1 viral proteins. Reverse transcriptase activity was detectable in the supernatant from the stable packaging line 1 day after induction, while vector titers peaked 5 days postinduction. Vector titers of up to 3.5 x 10(4) infectious units/ml (IU/ml) were maintained through 8 months following the establishment of the cell line. Lineage-specific gene delivery can be achieved from this established cell line as viral stocks obtained specifically infect CD4(+) target cells. Moreover, this cell line provides a safe and easy to use system for screening of drugs that inhibit HIV-1 replication. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9740788     DOI: 10.1006/viro.1998.9327

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  6 in total

1.  RD2-MolPack-Chim3, a packaging cell line for stable production of lentiviral vectors for anti-HIV gene therapy.

Authors:  Anna Stornaiuolo; Bianca Maria Piovani; Sergio Bossi; Eleonora Zucchelli; Stefano Corna; Francesca Salvatori; Fulvio Mavilio; Claudio Bordignon; Gian Paolo Rizzardi; Chiara Bovolenta
Journal:  Hum Gene Ther Methods       Date:  2013-08-03       Impact factor: 2.396

Review 2.  Methods for gene transfer to the central nervous system.

Authors:  Boris Kantor; Rachel M Bailey; Keon Wimberly; Sahana N Kalburgi; Steven J Gray
Journal:  Adv Genet       Date:  2014       Impact factor: 1.944

3.  Toward the development of a virus-cell-based assay for the discovery of novel compounds against human immunodeficiency virus type 1.

Authors:  Martin E Adelson; Annmarie L Pacchia; Malvika Kaul; Robert F Rando; Yacov Ron; Stuart W Peltz; Joseph P Dougherty
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

4.  The human immunodeficiency virus type 1 ribosomal frameshifting site is an invariant sequence determinant and an important target for antiviral therapy.

Authors:  Preetha Biswas; Xi Jiang; Annmarie L Pacchia; Joseph P Dougherty; Stuart W Peltz
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

Review 5.  Gene delivery by lentivirus vectors.

Authors:  Adam S Cockrell; Tal Kafri
Journal:  Mol Biotechnol       Date:  2007-07       Impact factor: 2.860

Review 6.  Production of lentiviral vectors.

Authors:  Otto-Wilhelm Merten; Matthias Hebben; Chiara Bovolenta
Journal:  Mol Ther Methods Clin Dev       Date:  2016-04-13       Impact factor: 6.698

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.